Traders should monitor upcoming clinical milestones, especially SAFEGUARD trial enrollment progress and biomarker/data readouts. Positive Phase 2b results could significantly re-rate the stock given the lack of disease-modifying therapies in T1D and SAB-142’s potential best-in-class profile.
SABS drugs
SABS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 10 $4.10entry
- T+1 · 8mo ago +11.71%α +11.81% · $4.58
- T+5 · 8mo ago −0.73%α +0.17% · $4.07
- T+20 · 7mo ago −9.02%α −8.87% · $3.73
- T+60 · 6mo ago −18.05%α −29.73% · $3.36
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SAB Biotherapeutics released Phase 1 data for its investigational therapy SAB-142 in established type 1 diabetes (T1D), showing early signals of C-peptide preservation, a marker of endogenous insulin production, in treated patients compared to placebo. While the cohort was small (n=6) and results are exploratory, the data support the drug's biological mechanism and provide momentum ahead of the ongoing Phase 2b SAFEGUARD trial in new-onset T1D, with topline results expected in 2H 2027.
Key Facts
- Phase 1 T1D cohort included 6 adult patients: 4 received SAB-142 (2.5 mg/kg), 2 received placebo.
- SAB-142-treated patients (n=4) showed no decrease in C-peptide at Day 120 vs. baseline; mean levels were preserved or increased.
- One placebo patient showed a decline in C-peptide consistent with expected disease progression; the second placebo patient discontinued early.
- Data align with SAB-142’s mechanism of action and prior biomarker evidence of T-cell modulation.
- SAFEGUARD Phase 2b registrational trial in new-onset T1D is ongoing, with global enrollment and topline data expected in 2H 2027.
Financial Impact
No direct financial impact from this release; potential long-term value hinges on Phase 2b success in a high-unmet-need indication.
Risk Factors
- Small sample size (n=4 active, n=1 placebo) limits statistical power and generalizability.
- Phase 1 data are exploratory and from established T1D patients, while the registrational trial is in new-onset T1D, a different population.
- Forward-looking statements carry high uncertainty; clinical failure risk remains significant.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252675 |
Track record
15 reports on SABS
3 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +15.67% at T+20 after the Oct 13, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $2.96 Now $3.00 +1.35% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $2.94 Now $3.00 +2.04% settles Dec 4
- Oct 22, 202625d ago 25-NSE Neutral 2/10 Entry $2.84 Now $3.00 +5.63% settles Nov 20
- Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.68 to $3.07 Now $3.00 +11.94% ▲ +14.55% +18.16% vs SPY
- Oct 13, 20264w ago Press Release Bullish 5/10 Entry $2.68 to $3.10 Now $3.00 +11.94% ▲ +15.67% +19.34% vs SPY
- Jul 7, 202618w ago 8-K Bullish 4/10 Entry $3.90 to $3.79 Now $3.00 −23.08% ▼ −2.82% −4.15% vs SPY
- May 29, 202624w ago Press Release Neutral 3/10 Entry $3.60 to $3.90 Now $3.00 −16.67% ▲ +8.33% +10.13% vs SPY
- May 12, 202626w ago Press Release Bearish 7/10 Entry $3.62 to $3.31 Now $3.00 +17.13% ▲ +8.56% +6.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers